Inflammatory Bowel Disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is an umbrella term used to describe a group of autoimmune conditions characterized by chronic, relapsing inflammation of the gastrointestinal tract. The tumour necrosis factor superfamily member 14 (TNFSF14), also known as LIGHT, is a pleiotropic cytokine with diverse roles in immune regulation. Here, we review the multifaceted involvement of LIGHT in intestinal inflammation, particularly its dual capacity to both promote immune activation and facilitate inflammation resolution in the context of IBD. We explore the molecular mechanisms of LIGHT signalling through its receptors, Herpes Virus Entry Mediator (HVEM) and Lymphotoxin-β Receptor (LTβR), and how these distinct interactions dictate its pro-inflammatory or regulatory functions. Finally, we review the therapeutic potential of targeting this pathway, highlighting the results of recent clinical trials and exploring future strategies aimed at restoring immune homeostasis in patients with IBD.

Mousa, R., Invernizzi, P., Jones, J., Mousa, H. (2025). TNFSF14 (LIGHT) in intestinal inflammation: balancing immune activation and resolution in IBD. FRONTIERS IN IMMUNOLOGY, 16 [10.3389/fimmu.2025.1657071].

TNFSF14 (LIGHT) in intestinal inflammation: balancing immune activation and resolution in IBD

Invernizzi P.;
2025

Abstract

Inflammatory Bowel Disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is an umbrella term used to describe a group of autoimmune conditions characterized by chronic, relapsing inflammation of the gastrointestinal tract. The tumour necrosis factor superfamily member 14 (TNFSF14), also known as LIGHT, is a pleiotropic cytokine with diverse roles in immune regulation. Here, we review the multifaceted involvement of LIGHT in intestinal inflammation, particularly its dual capacity to both promote immune activation and facilitate inflammation resolution in the context of IBD. We explore the molecular mechanisms of LIGHT signalling through its receptors, Herpes Virus Entry Mediator (HVEM) and Lymphotoxin-β Receptor (LTβR), and how these distinct interactions dictate its pro-inflammatory or regulatory functions. Finally, we review the therapeutic potential of targeting this pathway, highlighting the results of recent clinical trials and exploring future strategies aimed at restoring immune homeostasis in patients with IBD.
Articolo in rivista - Review Essay
BTLA (B and T lymphocyte attenuator); Crohn’s disease; DcR3 (TNFRSF6B); HVEM (TNFRSF14); inflammatory bowel disease (IBD); LIGHT (TNFSF14); LTβR (Lymphotoxin-β receptor); ulcerative colitis;
English
15-set-2025
2025
16
1657071
open
Mousa, R., Invernizzi, P., Jones, J., Mousa, H. (2025). TNFSF14 (LIGHT) in intestinal inflammation: balancing immune activation and resolution in IBD. FRONTIERS IN IMMUNOLOGY, 16 [10.3389/fimmu.2025.1657071].
File in questo prodotto:
File Dimensione Formato  
Mousa et al-2025-Frontiers in Immunology-VoR.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Creative Commons
Dimensione 2.57 MB
Formato Adobe PDF
2.57 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/592601
Citazioni
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
Social impact